L'INIBITORE DELLA RENINA REMIKIRENE (RO 42-5892), IN PAZIENTI IPERTESI IN TRATTAMENTO DIURETICO CRONICO: PROFILO ENDOCRINO ED EFFETTI EMODINAMICI SISTEMICI E RENALI

Fifteen patients whose diastolic blood pressure (BP) was between 90-114 mmHg despite at least 2 weeks of therapy with once daily 25 mg hydrochlorothiazide (HCT) were randomized in a double-blind fashion to receive a single dose of either placebo or one of 2 doses of Remikiren (RMK) (200 or 400 mg) in addition to HCT. BP, HR, GFR, RPF, PRA, and IRR were measured 2 days before and on the randomization day. PRA reduced and IRR increased in a dose-dependent manner after both doses of RMK. BP decreased dose dependently mainly at the 6th hour postdose; HR did not change. While the mean GFR and RPF remained stable in the 3 groups, one patient in each RMK group exhibited a marked increase in RPF. These results indicate that both single doses of RMK, given in addition to diuretic therapy, are well tolerated. Moreover, despite pre-activation of the RAS, no large BP decreases nor any changes in kidney function could be demonstrated.